EMA committee recommends approval of Bristol Myers’ repotrectinib to treat advanced ROS1-positive NSCLC & NTRK-positive solid tumours: Princeton, New Jersey Monday, November 18, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback